These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 30588904)

  • 61. Impact of Current Antipsychotic Medications on Comparative Mortality and Adverse Events in People With Parkinson Disease Psychosis.
    Ballard C; Isaacson S; Mills R; Williams H; Corbett A; Coate B; Pahwa R; Rascol O; Burn DJ
    J Am Med Dir Assoc; 2015 Oct; 16(10):898.e1-7. PubMed ID: 26239690
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A New Hope in Alzheimer's Disease Psychosis: Pimavanserin.
    Kurhan F; Akın M
    Curr Alzheimer Res; 2023; 20(6):403-408. PubMed ID: 37641988
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Psychosis in Parkinson's Disease: Current Treatment Options and Impact on Patients and Caregivers.
    Segal GS; Xie SJ; Paracha SU; Grossberg GT
    J Geriatr Psychiatry Neurol; 2021 Jul; 34(4):274-279. PubMed ID: 34219522
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Modern approaches to treatment of psychosis in Parkinson's disease].
    Cozac VV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(10):103-109. PubMed ID: 28635863
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Unmet needs in the diagnosis and treatment of Parkinson's disease psychosis and dementia-related psychosis.
    Sabbagh M; Small GW; Isaacson SH; Torres-Yaghi Y; Pagan F; Pahwa R
    Int J Psychiatry Clin Pract; 2023 Mar; 27(1):69-81. PubMed ID: 35574992
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive-enhancing medications.
    Espay AJ; Guskey MT; Norton JC; Coate B; Vizcarra JA; Ballard C; Factor SA; Friedman JH; Lang AE; Larsen NJ; Andersson C; Fredericks D; Weintraub D
    Mov Disord; 2018 Nov; 33(11):1769-1776. PubMed ID: 30387904
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Risk of long-term care admissions among Medicare beneficiaries treated with pimavanserin or quetiapine for Parkinson's disease psychosis in USA: a retrospective administrative claims database analysis.
    Rajagopalan K; Rashid N; Doshi D
    J Comp Eff Res; 2024 Jan; 13(1):e230114. PubMed ID: 38099518
    [No Abstract]   [Full Text] [Related]  

  • 68. Patients treated with pimavanserin or quetiapine for Parkinson's disease psychosis: analysis of health resource utilization patterns among Medicare beneficiaries.
    Rajagopalan K; Rashid N; Doshi D
    J Med Econ; 2023; 26(1):769-776. PubMed ID: 37272069
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Treating psychosis in movement disorder patients: a review.
    Borek LL; Friedman JH
    Expert Opin Pharmacother; 2014 Aug; 15(11):1553-64. PubMed ID: 24846479
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Screening, Diagnosis, and Management of Parkinson's Disease Psychosis: Recommendations From an Expert Panel.
    Pahwa R; Isaacson SH; Small GW; Torres-Yaghi Y; Pagan F; Sabbagh M
    Neurol Ther; 2022 Dec; 11(4):1571-1582. PubMed ID: 35906500
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Novel pharmaceuticals in the treatment of psychosis in Parkinson's disease.
    Broadstock M; Ballard C; Corbett A
    Expert Rev Clin Pharmacol; 2014 Nov; 7(6):779-86. PubMed ID: 25301532
    [TBL] [Abstract][Full Text] [Related]  

  • 72. QTc Interval Prolongation with Therapies Used to Treat Patients with Parkinson's Disease Psychosis: A Narrative Review.
    Torres-Yaghi Y; Carwin A; Carolan J; Nakano S; Amjad F; Pagan F
    Neuropsychiatr Dis Treat; 2021; 17():3791-3818. PubMed ID: 34992373
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The Efficacy and Safety of Antipsychotic Medications in the Treatment of Psychosis in Patients with Parkinson's Disease.
    Divac N; Stojanović R; Savić Vujović K; Medić B; Damjanović A; Prostran M
    Behav Neurol; 2016; 2016():4938154. PubMed ID: 27504054
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Pimavanserin as treatment for Parkinson's disease psychosis.
    Fox SH
    Lancet; 2014 Feb; 383(9916):494-6. PubMed ID: 24183566
    [No Abstract]   [Full Text] [Related]  

  • 75. Health care resource utilization patterns among patients with Parkinson's disease psychosis: analysis of Medicare beneficiaries treated with pimavanserin or other-atypical antipsychotics.
    Rajagopalan K; Rashid N; Kumar S; Doshi D
    J Med Econ; 2023; 26(1):34-42. PubMed ID: 36444507
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Healthcare resource utilization among nursing home residents with Parkinson's disease psychosis: an analysis of Medicare beneficiaries treated with pimavanserin or other-atypical antipsychotics.
    Rajagopalan K; Rashid N; Gopal D; Doshi D
    J Comp Eff Res; 2024 Jul; 13(7):e240038. PubMed ID: 38850129
    [No Abstract]   [Full Text] [Related]  

  • 77. The effects of treatment with pimavanserin on activities of daily living in patients with Parkinson's disease psychosis: a 16-week, single-arm, open-label study.
    Evidente VGH; DeKarske D; Coate B; Abler V
    Ther Adv Neurol Disord; 2024; 17():17562864241228350. PubMed ID: 38476466
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The Safety of Pimavanserin for Parkinson's Disease and Efforts to Reduce Antipsychotics for People With Dementia.
    Schneider LS
    Am J Psychiatry; 2022 Aug; 179(8):519-521. PubMed ID: 35921393
    [No Abstract]   [Full Text] [Related]  

  • 79. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Neurophysiological treatment effects of mesdopetam, pimavanserin and clozapine in a rodent model of Parkinson's disease psychosis.
    Stan TL; Ronaghi A; Barrientos SA; Halje P; Censoni L; Garro-Martínez E; Nasretdinov A; Malinina E; Hjorth S; Svensson P; Waters S; Sahlholm K; Petersson P
    Neurotherapeutics; 2024 Mar; 21(2):e00334. PubMed ID: 38368170
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.